ペンシルベニア州に拠点を置く JBS Science は本日、国立がん研究所から中小企業イノベーション研究 IIB に対して 3 万ドルのブリッジ賞を受賞したと発表しました。同社は、初期肝細胞がん (HCC) の尿 DNA スクリーニングである最初のリキッド バイオプシー製品を開発しました。
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of 肝臓がん. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating 腫瘍 DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBSは、肝臓がん尿検査の開発を進めるため、ジョンズ・ホプキンス大学医療センターのジェームズ・ハミルトン氏とトーマス大学病院のヒエウォン・ハン氏と協力したと発表した。
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
